ABCB4 Gene (ATP Binding Cassette Subfamily B Member 4)
ABCB4: A key transporter in biliary phospholipid secretion and its role in cholestatic liver diseases and drug-induced liver injury.
Gene Information Card
| Symbol | ABCB4 |
|---|---|
| Full Name | ATP Binding Cassette Subfamily B Member 4 |
| Gene Type | Protein coding |
| Chromosomal Location | 7q21.12 |
| NCBI Gene ID | 5244 ncbi.nlm.nih.gov/gene/5244 |
| Ensembl ID | ENSG00000005471 |
| UniProt ID | P21439 |
| OMIM ID | 171060 |
| HGNC ID | 45 |
| Aliases | MDR3, MDR2, PFIC3, ABC21, GBD1 |
Description
The ABCB4 gene encodes the multidrug resistance protein 3 (MDR3), a member of the ATP-binding cassette (ABC) transporter superfamily. MDR3 is primarily expressed in the canalicular membrane of hepatocytes and functions as a floppase that translocates phosphatidylcholine from the inner to the outer leaflet of the canalicular membrane, facilitating its secretion into bile. This phospholipid secretion is essential for micelle formation and protection of the biliary epithelium from detergent bile salts. Mutations in ABCB4 cause progressive familial intrahepatic cholestasis type 3 (PFIC3), low phospholipid-associated cholelithiasis (LPAC), and intrahepatic cholestasis of pregnancy (ICP).
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Progressive Familial Intrahepatic Cholestasis 3 (PFIC3) | Loss-of-function mutations impair phosphatidylcholine secretion, leading to toxic bile salt accumulation and progressive liver damage. | ClinVar, OMIM #171060 |
| Low Phospholipid-Associated Cholelithiasis (LPAC) | Partial deficiency of MDR3 reduces biliary phospholipid levels, promoting cholesterol gallstone formation and intrahepatic sludge. | OMIM #600803, PubMed |
| Intrahepatic Cholestasis of Pregnancy (ICP) | Heterozygous ABCB4 variants reduce transporter activity, exacerbated by hormonal changes, causing pruritus and elevated bile acids. | ClinVar, OMIM #147480 |
| Drug-Induced Liver Injury (DILI) | ABCB4 polymorphisms may increase susceptibility to cholestatic DILI by impairing biliary phospholipid secretion. | PubMed, ClinVar |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Liver | 12.8 | High |
| Gallbladder | 8.5 | Medium |
| Small Intestine | 3.2 | Low |
| Kidney | 1.1 | Not detected |
| Lung | 0.5 | Not detected |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HepG2 | 15.2 | Hepatocellular carcinoma cell line; high expression |
| Huh-7 | 11.4 | Hepatoma cell line; moderate expression |
| Caco-2 | 2.1 | Colorectal adenocarcinoma; low expression |
| HEK293 | 0.3 | Embryonic kidney; not detected |
Data source:Human Protein Atlas(proteinatlas.org)
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.504C>T (p.Arg168Cys) | Missense | Common in PFIC3 | Loss of function; reduced phospholipid transport |
| c.959C>T (p.Thr320Ile) | Missense | Associated with LPAC | Partial loss of function; decreased floppase activity |
| c.1331T>C (p.Val444Ala) | Missense | Polymorphism (rs2109505) | Moderate effect; risk factor for ICP and DILI |
| c.1769G>A (p.Arg590Gln) | Missense | Rare in PFIC3 | Loss of function; impaired ATP binding |
Mutation functional classification
Loss of Function (LOF)
Most PFIC3-associated mutations (e.g., p.Arg168Cys, p.Arg590Gln) cause complete or near-complete loss of phosphatidylcholine floppase activity, leading to severe cholestasis.
Gain of Function (GOF)
No gain-of-function mutations have been reported for ABCB4.
Dominant Negative (DN)
Some heterozygous missense variants (e.g., p.Thr320Ile) may exert a dominant-negative effect by disrupting dimerization or ATPase activity, contributing to LPAC or ICP.
View complete mutation data:
Gene Ontology (GO)
| • GO:0005524~ATP binding | • GO:0017127~cholesterol floppase activity |
| • GO:0015431~phosphatidylcholine floppase activity | • GO:0015908~phosphatidylcholine transport |
| • GO:0016324~apical plasma membrane | • GO:0042493~response to drug |
| • GO:0032869~cellular response to bile acid |
Pathways
• Bile secretion (KEGG hsa04976)
• ABC transporters (KEGG hsa02010)
• Phospholipid homeostasis (Reactome R-HSA-1483206)
Protein Summary
MDR3 (ABCB4) is a 1279-amino acid transmembrane glycoprotein with two nucleotide-binding domains (NBDs) and two transmembrane domains (TMDs). It functions as a homodimer or heterodimer with other ABC transporters. The protein is localized to the canalicular membrane of hepatocytes and uses ATP hydrolysis to translocate phosphatidylcholine into bile. This activity is critical for biliary lipid secretion and protection against bile salt toxicity. Structural mutations in the NBDs or TMDs disrupt ATPase activity or substrate recognition, leading to cholestatic liver diseases.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| ABCB4 Knockout HEK293 Cell Line | EDJ-KQ3577 | Human | 5244 | Details Get a Quote |
| ABCB4 Knockout HeLa Cell Line | EDJ-KQ54132 | Human | 5244 | Details Get a Quote |
| ABCB4 Knockout A-549 Cell Line | EDJ-KQ62622 | Human | 5244 | Details Get a Quote |
| ABCB4 Knockout HCT 116 Cell Line | EDJ-KQ71093 | Human | 5244 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records